The latest at MBC Biolabs
The latest at MBC Biolabs
Resident Company, Iaterion Inc., Received Funding To Accelerate Development of Women’s Health and Oncology Platform
Iaterion, Inc. received financing of undisclosed amount from Capital K, a venture capital fund in Silicon Valley, California
Newsletter February 2024
February Highlights: Special Announcements, Events and New Companies!
Newsletter January 2024
A Decade of Innovation: MBC BioLabs Celebrates Its 10-Year Anniversary
Integrated Biosciences Announces Nature Publication Identifying New Class of Antibiotics Discovered Via Company’s AI-Powered Platform
Publication validates the use of explainable deep learning in drug discovery and identifies a new class of antibiotics, one of the few in 60 years
Newsletter December 2023
December Highlights: Golden Ticket Opportunities, Exciting News from Our Community and Year-End Celebrations!
Kate Hudson Joins Symbiome as Creative Advisor
Academy Award-nominated actress Kate Hudson, an avid Symbiome customer, has joined the MBC resident company as Creative Advisor.
MBC BioLabs Alum, Loyal, Makes Headlines with their Pioneering Longevity Drugs for Dogs
Aiming to bridge the longevity gap between breeds, Loyal, a pet longevity company, is on the verge of a veterinary breakthrough
Newsletter November 2023
November News: Golden Achievements, Opportunities and Lots of Exciting Events!
Newsletter October 2023
October Unveiled: Golden Ticket Opportunities, Exciting Events and News from Our Community!
Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
LabCentral, BioLabs, and MBC BioLabs announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform.
Astellas Future Innovator Prize 2023
Apply until November 3, 2023, for Astellas Future Innovator Prize
Bristol Myers Squibb Golden Ticket 2023
Apply until September 18!
CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis
Ionic Liquids - Changing the Game One Indication at a Time
This Startup Just Raised $26 Million To Develop Safer Gene Editing Tools
Amber Bio Raises 26M to Develop Safer Gene-Editing Tools
UCSF researchers’ startup aims to stop allergies — starting with babies’ guts
UCSF spinout targets allergic diseases by resetting babies' guts
Eisai Innovation, Inc. Golden Ticket 2023
Apply until August 25!
Newsletter June 2023
June Highlights: Exciting News from Our Resident Companies, Events & Partnership Announcements!
Nitto Golden Ticket 2023 Winner
Acrobat Genomics is the winner!
ONO Golden Ticket 2023
Apply until May 23rd!